Securities code: Sichuan Huiyu Pharmaceutical Co.Ltd(688553) securities abbreviation: Sichuan Huiyu Pharmaceutical Co.Ltd(688553) Announcement No.: 2022027 Sichuan Huiyu Pharmaceutical Co.Ltd(688553)
Announcement on voluntary disclosure of obtaining drug registration certificate
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Sichuan Huiyu Pharmaceutical Co.Ltd(688553) (hereinafter referred to as “the company”) learned from the information announcement on the website of the State Drug Administration (hereinafter referred to as “the State Drug Administration”) on April 6 that the company’s product levetiracetam concentrated solution for injection has been approved and registered, and the drug approval number is Guoyao Zhunzi h20223181. The relevant information is hereby announced as follows:
1、 Basic information of drugs
Drug name: levetiracetam concentrated solution for injection
Dosage form injection
Specification: 5ml: 500mg
The indications are used for the treatment of partial seizures (with or without secondary generalized seizures) in adults and children over 4 years old.
This product can replace the administration when the patient is temporarily unable to use oral preparation.
Applicant 856853
Acceptance No.: cyhs2000772
Drug approval No.: gyzz h20223181
2、 Impact on the company and risk tips
The company has carried out relevant preparations for the sales of new drugs in the early stage of listing, but the specific sales situation may be affected by many factors such as changes in the market environment and sales channels, which is uncertain. It will not have a significant impact on the company’s operating performance in the short term. Please make careful decisions and pay attention to preventing investment risks.
It is hereby announced.
Sichuan Huiyu Pharmaceutical Co.Ltd(688553) board of directors April 7, 2022
